CNS Pharmaceuticals Raises $22.5M, Stock Jumps 258%

CNS Pharmaceuticals announced a private placement of 650,000 shares at $2.30 and pre‑funded warrants, targeting $22.5 million gross proceeds.
The financing, backed by ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners, is set to close around May 5, 2026.
Proceeds will fund acquisition of clinical‑stage assets, working capital, and support out‑licensing of glioblastoma programs Berubicin and TPI‑287.
Shares surged 257.5% on the news, reflecting strong market reaction to the capital raise.